Zoledronic acid

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Prostate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated

Conditions

Prostate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated

Trial Timeline

Jan 1, 2004 → —

NCT ID

NCT00172016

About Zoledronic acid

Zoledronic acid is a approved stage product being developed by Novartis for Prostate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated. The current trial status is completed. This product is registered under clinical trial identifier NCT00172016. Target conditions include Prostate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated.

What happened to similar drugs?

20 of 20 similar drugs in Prostate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated were approved

Approved (20) Terminated (4) Active (0)

✅EnzalutamideAstellas PharmaApproved

✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved

✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved

✅EnzalutamideAstellas PharmaApproved

✅Enzalutamide + FlutamideAstellas PharmaApproved

✅LeuprolideAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01197300	Phase 3	Completed	Oct 25, 2010	Feb 27, 2019	Osteoporosis
NCT01087008	Approved	Completed	Apr 1, 2010	Jun 5, 2013	Multiple Myeloma
NCT01004510	Phase 2	Terminated	Nov 1, 2009	Apr 1, 2011	Malignant Pleural Effusion
NCT00909961	Phase 3	Completed	Nov 1, 2009	Dec 16, 2011	Postmenopausal Osteoporosis
NCT00966992	Phase 2	Terminated	Aug 1, 2009	Mar 1, 2010	Uterine Cervical Neoplasms
NCT00760370	Phase 2	Completed	Dec 1, 2008	Dec 1, 2011	Multiple Myeloma
NCT00774020	Approved	Completed	Oct 30, 2008	Jan 14, 2011	Paget's Disease of Bone
NCT00740129	Approved	Completed	Oct 21, 2008	Mar 14, 2011	Paget's Disease of the Bone
NCT00745485	Approved	Completed	Aug 1, 2008	—	Osteoporosis
NCT00477217	Phase 2	Withdrawn	Jan 1, 2008	May 1, 2009	Osteonecrosis
NCT00622505	Approved	Completed	Nov 7, 2007	Apr 3, 2012	Multiple Myeloma
NCT00982124	Phase 3	Completed	Oct 1, 2007	Apr 1, 2016	Osteogenesis Imperfecta
NCT01218035	Approved	Completed	May 1, 2007	Jun 1, 2011	Hip Osteoarthritis
NCT00434447	Approved	Completed	Dec 1, 2006	—	Bone Neoplasms
NCT00424983	Phase 1	Completed	Nov 1, 2006	Nov 1, 2009	Multiple Myeloma
NCT00391950	Phase 3	Terminated	Oct 1, 2006	—	Prostate Cancer
NCT00361595	Pre-clinical	Completed	Aug 1, 2006	Apr 1, 2008	Osteoporosis
NCT00334139	Approved	Completed	May 1, 2006	Jul 1, 2009	Prostate Cancer
NCT00391690	Approved	Completed	Feb 1, 2006	—	Prostate Cancer
NCT00375427	Phase 3	Completed	Feb 1, 2006	—	Breast Cancer With Bone Metastasis

Competing Products

20 competing products in Prostate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated

See all competitors

Product	Company	Stage	Hype Score
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRT	Nanobiotix	Phase 1/2	18
Pemetrexed	Eli Lilly	Phase 2	35
5 mg Tadalafil + Placebo + 0.2 mg Tamsulosin	Eli Lilly	Phase 3	40
SRF617 + etrumadenant + zimberelimab	Coherus BioSciences	Phase 2	17
Abemaciclib + Placebo + Abiraterone acetate + Prednisone	Eli Lilly	Phase 2/3	42
eFT508	eFFECTOR Therapeutics	Phase 2	17
Enhertu	Daiichi Sankyo	Phase 2	42
Ifinatamab deruxtecan + Docetaxel + Prednisone + Rescue Medication	Daiichi Sankyo	Phase 3	47
exatecan mesylate	Daiichi Sankyo	Phase 2	35
PLX3397	Daiichi Sankyo	Phase 2	27
Valemetostat + Darolutamide	Daiichi Sankyo	Phase 1	36
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)	Astellas Pharma	Phase 3	44
Enzalutamide	Astellas Pharma	Phase 2	35
Enzalutamide + Docetaxel + Prednisolone + Placebo	Astellas Pharma	Phase 3	40
Enzalutamide	Astellas Pharma	Phase 2	35
Enzalutamide + Metformin Hydrochloride	Astellas Pharma	Phase 1	29
degarelix + Goserelin	Astellas Pharma	Phase 3	40
Enzalutamide, 160mg, 40 mg soft capsules, once daily	Astellas Pharma	Pre-clinical	26
enzalutamide + abiraterone acetate + prednisone	Astellas Pharma	Phase 2	35
enzalutamide + abiraterone acetate + prednisone + Leuprolide acetate	Astellas Pharma	Phase 2	42